Vitamin D deficiency in fibromyalgia

Vitamin D deficiency is a widespread concern in chronic pain conditions. Prior research has shown that low vitamin D levels are associated with various musculoskeletal disorders. However, the extent of vitamin D deficiency in fibromyalgia remains unclear. No prior work had resolved whether this deficiency is specific to fibromyalgia or a general trend in similar patient groups. This gap motivated the study to investigate vitamin D levels in fibromyalgia patients. The study aimed to determine if vitamin D deficiency is prevalent in this population. It was already known that vitamin D plays a role in bone health and immune function. But the connection to fibromyalgia symptoms had not been fully explored. The researchers sought to address this uncertainty by measuring serum vitamin D levels in diagnosed fibromyalgia patients.

The study aimed to assess vitamin D levels in female fibromyalgia patients in a specific geographic population. The researchers wanted to determine how common vitamin D deficiency is in this group. They also sought to compare deficiency rates across age groups. The motivation for the study stemmed from anecdotal reports of high vitamin D deficiency in fibromyalgia populations. No prior work had resolved whether this was a regional or global phenomenon. The study focused on patients meeting ACR criteria for fibromyalgia. Exclusion criteria included systemic illness and abnormal laboratory results. The goal was to isolate fibromyalgia-specific vitamin D levels from other confounding factors.

The study was conducted at the Medical OPD of Civil Hospital Karachi from January to March 2009. Female patients diagnosed with fibromyalgia according to ACR criteria were included. Participants underwent physical examination and laboratory tests to exclude systemic illness. Blood tests measured CP, ESR, serum calcium, phosphate, and alkaline phosphatase. Serum vitamin D levels were then analyzed. Deficiency was defined as <20 ng/ml, insufficiency as 21-29 ng/ml, and sufficiency as ≥30 ng/ml. Forty patients were enrolled. The study compared vitamin D levels between younger and older age groups. Data collection included age, diagnosis status, and biochemical results.

Forty female fibromyalgia patients were included in the study. The mean age was 37.65 years with a standard deviation of 11.5 years. The mean vitamin D level was 17.41 ng/ml with a standard deviation of 5.497 ng/ml. Thirty-two patients (80%) had vitamin D deficiency, with a mean level of 15.85 ng/ml. Eight patients (20%) had vitamin D insufficiency, with a mean level of 23.64 ng/ml. Among patients under 45 years old, 22 (68.75%) had deficiency, with a mean level of 16.87 ng/ml. Ten patients aged 46-75 had deficiency, with a mean level of 16.09 ng/ml. These findings suggest a high prevalence of vitamin D deficiency in fibromyalgia patients. The results highlight a need for further population-based studies.

The study found a high prevalence of vitamin D deficiency in fibromyalgia patients in the studied population. The mean vitamin D level was below the sufficiency threshold for most participants. The authors propose that this deficiency may be a contributing factor to musculoskeletal symptoms in fibromyalgia. They suggest that vitamin D status should be considered in fibromyalgia management. The study's small sample size limits generalizability but highlights a significant trend. The authors recommend larger population-based studies to confirm these findings. They also suggest including non-fibromyalgia patients with musculoskeletal pain in future research. These conclusions are based on the observed data and do not imply causation.